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CASE REPORT
A 46-year-old never-smoker man presented to the emer-
gency room with a 4-day history of progressive cough and 
right-side chest wall pain in October 2011. A computed tomog-
raphy scan of his chest showed large anterior mediastinal and 
right pleural-based masses associated with pleural effusion. 
The tumor was confirmed to be squamous cell carcinoma 
by percutaneous gun biopsy of the right pleural-based mass 
(Fig. 1A). The tumor cells expressed KIT (Fig. 1B) and p63 
proteins, and the patient was diagnosed with thymic cancer. 
Even after two cycles of paclitaxel/cisplatin chemotherapy and 
a subsequent line of cyclophosphamide/doxorubicin/cisplatin 
chemotherapy, his pleural effusion increased and the primary 
anterior mediastinal mass progressed. He required frequent 
thoracentesis to relieve dyspnea. At that time, we evaluated 
whether the initially biopsied tumor specimen harbored KIT 
mutation, and identified a mutation in exon 11 (loss of aspartic 
acid at position 579: D579del).
After administration of imatinib (400 mg daily) since 
December 2011, the tumorous lesion has decreased to the 
range of partial response by the Response Evaluation Criteria 
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FIGURE 1.  Thymic carcinoma in a patient with an activating 
KIT mutation before treatment with imatinib: hematoxylin 
and eosin (×400) (A), immunohistochemical KIT staining 
(×400) (B).
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FIGURE 2.  Chest CT images at baseline and after 15 months of 
imatinib treatment showed a decrease in size with cystic change 
of the anterior mediastinal mass (A); the right pleural-based 
mass had nearly disappeared and pleural effusion decreased 
(B). Positron emission tomography–CT scans at the same time 
points also showed decreased FDG uptake in the correspond-
ing lesions of the anterior mediastinum (C) and pleura (D). CT, 
computed tomography; FDG, fluorodeoxyglucose.
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in Solid Tumors (Fig. 2). The patient is still on imatinib (total 
15 months) and is in good general condition.
DISCUSSION
Although KIT protein expression is prevalent in thymic 
neoplasms, KIT mutation has rarely been observed.1,2 Since 
the first report of KIT mutation and tumoral response to ima-
tinib in thymic cancer in 2004, a few similar cases have been 
reported.3,4
In this case, we demonstrated the presence of a novel 
somatic deletion mutation involving the proto-oncogene 
KIT in thymic cancer. The patient currently shows a pro-
longed partial response to imatinib with no significant tox-
icity. Among the many KIT exon 11 mutations, a deletion 
in codon 579(Asp) in the juxtamembrane region of the KIT 
gene was reported in a gastrointestinal stromal tumor,5 but 
has never been reported in thymic cancer. As in our case, 
that tumor was reported to show a good response to imatinib 
therapy.
To date, there have been few treatment options for 
metastatic thymic carcinoma, and its outcome is generally 
disappointing. In agreement with previous reports, our study 
suggests that the KIT pathway can be an important driving 
oncogenic pathway and can be a useful target of molecular 
therapy such as imatinib.
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